Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Toulouse III University and Larrey Hospital, Toulouse, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Toulouse
Treatments:Biologic therapyHospital:Toulouse III University and Larrey Hospital
Drugs:Journal:Link
Date:Jul 2013

Description:

Patients:
This study involved 38 metastatic melanoma patients with brain metastasis. The median patient age was 50 years and 68.4% were male.

Treatment:
Patients were treated with the biologic therapy agent called ipilimumab, which is a monoclonal antibody recognizing CTLA-4 that works to help the immune system attack tumor cells.

Toxicities:
There were eight treatment-related deaths due to intracranial hemorrhage and intracranial hypertension. Grade 3 fatigue and enterocolitis (inflammation of the digestive tract) were also reported.

Results:
The median overall survival was 3.3 months.

Support:
Study drug was provided by Bristol-Myers Squibb, makers of ipilimumab.

Correspondence: Dr. Nicolas Meyer; email: [email protected]



Back